Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1046-1059

  Nakamura, Satoki ^a   Yokota, Daisuke ^a   Tan, Lin ^a   Nagata, Yasuyuki ^a   Takemura, Tomonari ^a   Hirano, Isao ^a   Shigeno, Kazuyuki ^a   Shibata, Kiyoshi ^a   Fujisawa, Shinya ^b   Ohnishi, Kazunori ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

ALDH hi cells; Bcr Abl; c Myc; CML; THAP11

Indexed keywords

ABELSON KINASE; ALDEHYDE DEHYDROGENASE; BCR ABL PROTEIN; CD34 ANTIGEN; JANUS KINASE 2; MYC PROTEIN; SMALL INTERFERING RNA; STAT5 PROTEIN; THANATOS ASSOCIATED PROTEIN 11; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; GENE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; ODC GENE; P21 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; GENES, MYC; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPRESSOR PROTEINS;

EID: 84155165037     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26065     Document Type: Article

References (42)

1. Kurzrock R, Gutterman JU, Talpaz M,. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1998; 319: 990-8.
2. Rudkin CT, Hungerford DA, Nowell PC,. DNA Contents of chromosome Ph1 and chromosome 21 in human chronic granulocytic leukemia. Science 1964; 144: 1229-31.
3. Shtivelman E, Lifshitz B, Gale RP, Ganaani E,. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-4. (Pubitemid 15021190)
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON,. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-82.
5. Daley GQ, Van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30.
6. Sawyers CL, McLaughlin J, Witte ON,. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181: 307-13.
7. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-61. (Pubitemid 27458335)
8. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC,. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991; 11: 1107-13. (Pubitemid 21895462)
9. Carlesso N, Frank DA, Griffin JD,. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-20. (Pubitemid 26113953)
10. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS, Jr,. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12: 968-81. (Pubitemid 28204604)
11. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB,. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001; 20: 6188-95. (Pubitemid 32964431)
12. de Groot R, Raaijmarkers J, Lammers J, Jove R, Koenderman L,. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1995; 94: 1108-12. (Pubitemid 29361844)
13. Huang M, Dorsey JF, Epling-Burnette P, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002; 21: 8804-16. (Pubitemid 36132401)
14. Sawyers CL, Callahan W, Witte ON,. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901-10.
15. Xie S, Lin H, Sun T, Arlinghaus RB,. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002; 21: 7137-46. (Pubitemid 35305600)
16. Hoover RR, Gelach MJ, Koh EY, Daley GQ,. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20: 5826-35. (Pubitemid 32937952)
17. Hoffman B, Liebermann DA,. The proto-oncogene c-myc and apoptosis. Oncogene 1998; 17: 3351-3357. (Pubitemid 29043987)
18. Askew DS, Ashmun RA, Simmons BC, Cleaveland JL,. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-22. (Pubitemid 21924028)
19. Evan GI, Littlewood TD,. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44-9. (Pubitemid 23079645)
20. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodein G, Neiman PE, Collins SJ, Lobanenkov VV,. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 1996; 16: 2803-13.
21. Albert T, Wells J, Funk JO, Pullner A, Raschke EE, Stelzer G, Meisterernst M, Farnham PJ, Eick D,. The chromatin structure of the dual c-myc promoter P1/P2 is regulated by separate elements. J Biol Chem 2001; 276: 20482-90.
22. Chaudhary D, Miller DM,. The c-myc promoter binding protein (MBP-1) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. Biochemistry 1995; 34: 3438-45.
23. Izzo MW, Strachan GD, Stubbs MC, Hall DJ,. Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ. J Biol Chem 1999; 274: 19498-506.
24. Lin Y, Wong K, Calame K,. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997; 276: 596-9. (Pubitemid 27193684)
25. Zhu CY, Li CY, Li Y, Zhan YQ, Li YH, Xu CW, Xu WX, Sun HB, Yang XM,. Cell growth suppression by thanatos-associated protein 11(THAP11) is mediated by transcriptional downregulation of c-Myc. Cell Death Differentiation 2009; 16: 395-405.
26. Roussigne M, Kossida S, Lavigne AC, Clouaire T, Ecochard V, Glories A, Amalric F, Girard JP,. The THAP domain: a novel protein motif with similarity to the DNA-binding domain of P element transposase. Trends Biochem Sci 2003; 28: 66-9. (Pubitemid 36165133)
27. Pandey N, Mittal U, Srivastava AK, Mukerji M,. SMARCA2 and THAP11: potential candidates for polyglutamine disorders as evidenced from polymorphism and protein-folding simulation studies. J Hum Genet 2004; 49: 596-602. (Pubitemid 40385247)
28. Dejosez M, Krumenacker JS, Zitur LJ, Passeri M, Chu LF, Songyang Z, Thomson JA, Zwaka TP,. Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. Cell 2008; 133: 1162-74. (Pubitemid 351852919)
29. Nakamura S, Okinaka K, Hirano I, Ono T, Sugimoto Y, Shigeno K, Fujisawa S, Shinjo K, Ohnishi K,. KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leuk Res 2008; 32: 1358-65.
30. Boxer LM, Dang CV,. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-610. (Pubitemid 32928100)
31. Ryan KM, Birnie GD,. Cell-cycle progression is not essential for c-Myc to block differentiation. Oncogene 1997; 14: 2835-43. (Pubitemid 27313416)
32. Krishnaraju K, Hoffman B, Liebermann DA,. The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells. Blood 1998; 92: 1957-66. (Pubitemid 28446685)
33. Schmidt M, Nazarov V, Stevens L, Watson R, Wolff L,. Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol Cell Biol 2000; 20: 1970-81. (Pubitemid 30123813)
34. Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS, Boswell HS,. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 1995; 9: 1499-1507.
35. Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K,. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity 1997; 6: 449-57. (Pubitemid 27208200)
36. Digicaylioglu M, Lipton SA,. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-7. (Pubitemid 32772276)
37. La Rosa FA, Pierce JW, Sonenshein GE,. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 1994; 14: 1039-44. (Pubitemid 24036554)
38. Horita M, Andreu E, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL,. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977-84.
39. Lord JD, Mclntosh BC, Greenberg PD, Nelson BH,. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol 2000; 164: 2533-41. (Pubitemid 30115483)
40. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF,. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98: 181-91.
41. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K,. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileulemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-34. (Pubitemid 41040705)
42. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K,. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin (17-AAG). Cancer Res 2002; 62: 5761-9. (Pubitemid 35204733)